Preventions of viruses other than cytomegalovirus in solid organ transplantations
| Characteristic | Kidney (n=31) | Liver (n=25) | Heart (n=8) | Lung (n=8) |
|---|---|---|---|---|
| Herpes zoster prevention | ||||
| None | 24 (77) | 18 (72) | 2 (25) | 1 (13) |
| Prophylaxis | 7 (23) | 7 (28) | 6 (75) | 7 (88) |
| Acyclovir (oral) | 0 | 4 (16) | 6 (75) | 0 |
| Valacyclovir (oral) | 2 (7) | 0 | 0 | 0 |
| Valganciclovir (oral), included in CMV prophylaxis | 5 (16) | 3 (12) | 0 | 7 (88) |
| Duration of prophylaxis (mo) | 3 (1‒6) | 3 (1‒6) | 1 (1‒6) | 6 (3‒6) |
| EBV monitoring | ||||
| None | 25 (81) | 18 (72) | 7 (88) | 5 (63) |
| qPCR monitoring | 2 (7) | 0 | 0 | 0 |
| qPCR monitoring, if EBV D+/R– | 3 (10) | 5 (20) | 1 (13) | 0 |
| qPCR monitoring, if pretransplant EBV qPCR+ | 1 (3) | 2 (8) | 0 | 3 (38) |
| Duration of prophylaxis (mo) | 12 (3‒12) | 12 (6‒48) | 12 | 12 (12‒24) |
| BK virus monitoring | ||||
| None | 3 (10) | 0 | 0 | 0 |
| qPCR monitoring | 28 (90) | 0 | 0 | 0 |
| Blood | 14 (45) | 0 | 0 | 0 |
| Urine | 4 (13) | 0 | 0 | 0 |
| Blood+urine | 10 (32) | 0 | 0 | 0 |
| Duration of qPCR monitoring (mo) | 12 (3‒60) | 0 | 0 | 0 |
Values are presented as number (%) or median (range).
CMV, cytomegalovirus; EBV, Epstein-Barr virus; qPCR, quantitative polymerase chain reaction.